PharmAust has announced positive top-line data from its Phase 2 veterinary clinical study of monepantel (MPL) for the treatment of Canine B-Cell Lymphoma. The company plans to use this data to open an Investigational New Animal Drug (INAD) application with the United States Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) and proceed with studies in 2024 to support product registration.
PharmAust Limited (ASX:PAA)
PharmAust is a clinical-stage company developing novel targeted ALS and cancer therapeutics.
About Us
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.
Company Summary
Board & Management
Sam Wright has 20 years’ experience in the administration of ASX & LSE listed companies, corporate governance and corporate finance. He joined the Company as the Financial Controller in September 2006, was appointed as the Company Secretary in August 2007, and has been a Director of the Company since October 2008.
Mr Wright is Director and Company Secretary of a number of companies in Australia, North America and the United Kingdom. He is a member of the Australian Institute of Company Directors, the Financial Services Institute of Australasia, and the Governance Institute of Australia.
Mr Wright is the Managing Director of Perth-based corporate advisory firm Straight Lines Consultancy, specialising in the provision of corporate services to public companies.
Mr Wright has extensive experience in relation to public company responsibilities, including ASX, LSE and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, and shareholder relations with both retail and institutional investors.
John Clark joined PharmAust with over 20 years of pharmaceutical industry experience in phase I – IV clinical trials across numerous therapeutic areas and multiple geographical regions. Most recently, John served as Senior Project Manager at a Global CRO, leading the Clinical Operations team and providing cross-functional oversight on a national CNS trial. Before that, John held various clinical operations leadership roles responsible for implementing clinical programs. John has a proven project management and stakeholder engagement record, with a thorough knowledge of ICH-GCP and regulatory requirements. John earned his B.Sc. in Biomedical Sciences from the University of the West of England.
Marcus Hughes
Non-Executive Director
Mr Hughes brings more than 20 years’ experience with listed companies. He possesses extensive corporate finance experience, having led project financing and capital raisings in the industrial sector. He has held senior managerial, tax and finance roles with multi-national companies including Lend Lease, Fortescue Metals and Rio Tinto.
